1Globe Biomedical says biological safety testing likely to reach US$3 billion 2025

CENTRAL DISTRICT, Hong Kong - Oct. 9, 2020 - PRLog -- 1Globe Biomedical's financial analysts have predicted that the global market for biological safety testing is likely to expand at over 9.3% CAGR over the 5-year forecasted time period.

1Globe Biomedical's Chief Market Strategist commented on the biological safety testing saying "Based on product type, the instrument sector likely to dominate the global market for biological safety testing in the years to come.  Based on regional statistics, the Asia Pacific region is likely to have the most growth as there are many emerging economies.

1Globe Biomedical's Chief Market Strategist also added "The increasing demand in the biological industry and pharmaceutical industry for biological safety testing is likely to demonstrate significant growth in the next few years. The advancement in technology and increasing and the demand for cost effective products are the main factors which will propel growth in this market."

About Us - 1Globe Biomedical

1Globe Biomedical is a clinical stage biotechnology company pioneering the development of receptor T (1BioCARs™) therapies for cancer. Led by a world-class management team with significant experience in cell therapy, we are developing a pipeline of "off-the-shelf" receptor T cell therapy candidates with the goal of delivering readily available cell therapy faster, more reliably and at greater scale to more patients.

http://1globe-biomedical.com/about-us/history/index.html